The offering provides a large cash runway for IDEAYA's pipeline programs, reducing near-term financing risk. However, the 12%+ dilution combined with no disclosed revenue or earnings improvement for the quarter is a negative signal for existing holders. Monitor the company's next pipeline update for trial data that could justify the expanded share count. The 60-day lock-up expiration in early August 2026 may create an overhang if insiders sell into the market.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $28.84entry
- T+1 · 5mo ago +0.49%α −0.06% · $28.98
- T+5 · 5mo ago +8.39%α +7.96% · $31.26
- T+20 · 4mo ago +29.26%α +27.37% · $37.28
- T+60 · 2mo ago +38.21%α +33.82% · $39.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, generating net proceeds of approximately $323.6 million. This is a material dilutive event for a $2.5B market cap company. Stockholders' equity per share is diluted by this issuance, although the ~$323.6M in new cash extends the cash runway for clinical development.
Key Facts
- Sold 7,222,225 shares of common stock at $27.00/share and pre-funded warrants for 5,555,576 shares at $26.9999/warrant.
- Net proceeds of approximately $323.6 million after underwriting discounts and estimated expenses.
- Pre-funded warrants have an exercise price of $0.0001 per share, meaning investors effectively bought common stock exposure at the offering price minus a de minimis exercise price.
- Underwriters' option for 1,666,669 additional shares was exercised in full.
- The offering is dilutive, 7.2 million new common shares (~12%+ dilution pre-warrants exercise) against a pre-offering share base estimated from a $2.5B market cap at $27/share (~92.6M shares outstanding pre-offering), resulting in ~8% dilution from shares alone, plus potential further dilution from warrants.
- Lock-up agreements restrict insider sales for 60 days post-prospectus date.
Financial Impact
Company raised ~$323.6M in net cash. Dilution: 7.2M new shares + 5.6M warrant shares represent roughly 12-14% total potential dilution to existing holders.
Risk Factors
- Significant dilution from new shares and pre-funded warrants (~12-14% total potential dilution).
- No corresponding revenue or earnings catalyst disclosed in this filing.
- 60-day lock-up ends in August, creating potential selling pressure from insiders.
- For a pre-commercial biotech, clinical trial failures would magnify the impact of a larger share base.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-265833 |
| Document: d110954dex41.htm | 0001193125-26-265833 |
| Document: d110954d8k.htm | 0001193125-26-265833 |
| Document: d110954dex51.htm | 0001193125-26-265833 |
| Document: 0001193125-26-265833-index-headers.html | 0001193125-26-265833 |
| Document: 0001193125-26-265833-index.html | 0001193125-26-265833 |
| Document: 0001193125-26-265833.txt | 0001193125-26-265833 |
Track record
13 reports on IDYA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Viewing Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers